Published in Vaccine Weekly, August 17th, 2005
DOR and Cambrex entered into an agreement in January, 2005, under which Cambrex would provide process development and cGMP (current Good Manufacturing Processes) production services for the development and manufacture of clinical quantities of RiVax.
The companies' work has been conducted under a challenge grant totaling $6.4 million awarded to DOR in September, 2004,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly